CYCC's average Wall Street 12-month SP calculation is $17.50 (nearly a triple on a reverse split adjusted basis), which I believe fair if there is no partner catalyst within the next 12 months. However, if some news enters on the bus-dev front in 2013, a triple could get to $25 pretty quickly.
The above from today's Seeking Alpha article. Looks like they've done some homework on this one too.
Nov 1, 2012 recent HOD $7.77 and on Oct 15, 2012 a $7.93 HOD given the corrections on large surges has occurred buying in under $6 is a gift horse. Never look one in the mouth.
MARKET OUTPERFORM price target $25 inline for the triple sighted above.
Investors will probably agree with this review using their due diligence/fact checking.
For any of US that have been holding massive quantities for over a couple of years, $17.50 is about our BREAK-EVEN price; therefore, I certainly EXPECT $17.50 -- nothing less! Of course, that is
merely my opinion.
Now, for those who might want to say why didn't you buy more under $1--- my reply is-- where the
heck would I find the money, I WAS ALL IN!!
All in is not a strategy, but your loyalty may be rewarded eventually. Still, $17.50, while a good ways away, is not out of the question. I think that that is the reason that there were almost no short positions until last month.
Yep. I made a very nice profit on the rise to $4.00 back when (sold way too early, kicked myself, and then bought back in when it looked like it was settling down a little above $2.00). It was really stupid trading. I didn't have the patience (like tdeank has always advocated) to just put it out of my mind and let it sit until sap's final FDA approval.